Legal & General Group PLC Neoleukin Therapeutics, Inc. Transaction History

Legal & General Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 22, 2022	SELL	$0.92 - $2.25 $2,789 - $6,822	-3,032 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$4.65 - $7.75 $36,172 - $60,287	-7,779 Reduced 71.95%	3,032 $15,000
Q3 2021 Nov 15, 2021	BUY	$6.05 - $9.66 $40,111 - $64,045	6,630 Added 158.57%	10,811 $78,000
Q2 2021 Aug 12, 2021	SELL	$9.23 - $13.12 $6,359 - $9,039	-689 Reduced 14.15%	4,181 $39,000
Q1 2021 May 17, 2021	SELL	$11.26 - $15.78 $2,274 - $3,187	-202 Reduced 3.98%	4,870 $60,000
Q3 2020 Nov 13, 2020	SELL	$9.68 - $17.01 $9,476 - $16,652	-979 Reduced 16.18%	5,072 $61,000
Q2 2020 Aug 14, 2020	BUY	$9.95 - $17.05 $60,207 - $103,169	6,051 New	6,051 $100,000

199K

Ticker NLTX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,579,900
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.